Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$46.28M
TTM
Current Assets
Q1 2023
Current Liabilities
Q1 2023
Current Ratio
59.04%
Q1 2023
Total Assets
Q1 2023
Total Liabilities
Q1 2023
Book Value
-$6.299M
Q1 2023
Cash
Q1 2023
P/E
-0.0000003025
Nov 29, 2024 EST
Free Cash Flow
-$37.24M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

No data

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $14.00

About 9 METERS BIOPHARMA, INC.

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 10 full-time employees. The company went IPO on 2016-07-08. The firm has filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the Eastern District of North Carolina.

Industry: Pharmaceutical Preparations Peers: NRX Pharmaceuticals, Inc. Eton Pharmaceuticals, Inc. Enliven Therapeutics, Inc. JOHNSON & JOHNSON Journey Medical Corp OPIANT PHARMACEUTICALS, INC. Medicine Man Technologies, Inc. Mystic Holdings Inc./NV Odonate Therapeutics, Inc.